Business Context and Reporting Period
Company: Exelixis, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: Exelixis is a biotechnology company focused on discovering and developing novel drug therapies for cancer and other proliferative diseases using an integrated discovery platform based on comparative genomics and model system genetics. The company also leverages its technology for agrochemical and agricultural applications through joint ventures.
Key Financial Metrics
| Metric (in thousands) | 2003 | 2002 |
|---|---|---|
| Total Revenues | $51,540 | $44,322 |
| Net Loss | $(94,774) | $(86,130) |
| Loss Per Share (Basic & Diluted) | $(1.45) | $(1.52) |
| Research & Development Expenses | $127,622 | $112,014 |
| Cash, Cash Equivalents & Short-term Investments | $241,930 | $221,987 |
| Working Capital | $189,968 | $178,914 |
| Long-term Debt (excluding current portion) | $99,437 | $58,973 |
| Accumulated Deficit | $(382,128) | $(287,354) |
Note: The company has incurred net losses since inception and expects to continue incurring losses as it advances its drug discovery and clinical development programs.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 16% to $51.5 million, driven primarily by the October 2002 collaboration with GlaxoSmithKline (GSK) and increased activity in chemistry collaborations. This offset the conclusion of collaborations with Pharmacia and Protein Design Labs.
- Expense Increases: Research and development (R&D) expenses rose 14% to $127.6 million due to expanded drug discovery operations, increased personnel costs, and higher consulting fees related to advancing clinical candidates (XL784, XL119).
- Debt Expansion: Long-term debt increased significantly due to an additional $30 million drawdown on the GSK loan facility in December 2003, bringing total GSK borrowings to $55 million.
- Restructuring: The company recorded a $925,000 restructuring charge in Q3 2003 related to a reduction in force of 61 research personnel and the closure of its Tübingen, Germany facility.
- Capital Raise: In 2003, the company completed a follow-on public offering of approximately 11.3 million shares, generating net proceeds of $74.7 million.
Guidance, Outlook, and Risks
Outlook and Pipeline
- Clinical Pipeline:
- XL119: Phase 3 trial for bile duct tumors expected to initiate in Q2 2004.
- XL784: Phase 1 trials ongoing; development path for renal and cardiovascular disease planned for 2004.
- XL647 & XL999: IND applications expected in Q1 and Q2 2004, respectively.
- XL844: IND application expected in early 2005.
- Liquidity: Management anticipates that current cash, investments, and collaborator funding will support operations for at least the next two years. However, substantial additional capital will be required for future clinical trials and commercialization.
Risks and Contingencies
- Profitability: The company has a history of net losses and expects to continue incurring losses. There is no guarantee of achieving profitability.
- Collaboration Dependence: A significant portion of revenue is derived from a few major collaborators (Bayer, Bristol-Myers Squibb, GSK). Termination or failure to renew these agreements could materially impact revenue.
- Regulatory Risk: Product candidates are subject to lengthy and uncertain regulatory processes. Clinical trials may fail to demonstrate safety or efficacy.
- Manufacturing: The company lacks internal manufacturing capabilities and relies on third parties for clinical trial supplies.
- Key Personnel: The departure of the former Chief Scientific Officer at the end of 2003 poses a risk to ongoing operations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $241.9 million cash position against the projected burn rate for advancing multiple clinical candidates (XL119, XL784, XL647, XL999).
- Collaboration Terms: Review the specific milestone triggers and termination clauses in the GSK, Bayer, and Bristol-Myers Squibb agreements, as these drive future revenue recognition.
- Debt Covenants: Examine the terms of the $85 million GSK loan facility and other debt instruments for covenants that could restrict operations or require equity conversion.
- Restructuring Costs: Monitor the actual costs associated with the Tübingen facility closure and workforce reduction, as additional expenses of approximately $1.3 million were estimated for Q1 2004.
- Intellectual Property: Assess the status of the 195 pending patent applications and 47 issued patents, given the high risk of IP litigation in the biotechnology sector.